You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Dr Reddys Labs spurts on launching OTC eye allergy drop in US

Capital Market 

Dr Reddys Laboratories jumped 3.24% to Rs 4,781.40 after the drug major announced the launch of over-the-counter Olopatadine Hydrochloride Ophthalmic Solution in the US market.

Dr. Reddy's Laboratories on Thursday announced the launch of over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the store-brand equivalents of Pataday Once Daily Relief and Pataday Twice Daily Relief, in the US market.

The solution is indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander. It is also indicated for the temporary relief of red eyes.

The Pataday brand had US sales of approximately $31 million since the launch in March 2020 according to IRi.

Shares of Dr Reddys Laboratories jumped 4.24% on Wednesday after the drug major said it will co-operate with Russia's sovereign wealth fund on clinical trials and distribution of the Sputnik V vaccine in India. Deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India.

The stock hit an all-time high of Rs 4,783.90 today. It has surged 91.43% from its 52-week low of Rs 2,497.60 hit on 19 March 2020.

The drug major's consolidated net profit skid 12.1% to Rs 594.60 crore on 14.9% jump in net sales to Rs 4,417.50 crore in Q1 June 2020 over Q1 June 2019.

Dr Reddy's Laboratories is a pharmaceutical company. Through its three businesses - pharmaceutical services and active ingredients, global generics and proprietary products - the company offers a portfolio of products and services, including active pharmaceutical ingredients (API), custom pharmaceutical services (CPI), generics, biosimilars, differentiated formulations and new chemical entities.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, September 17 2020. 11:41 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU